{'fraction_non_alphanumeric': 0.026722925457102673, 'fraction_numerical': 0.0, 'mean_word_length': 5.137931034482759, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Animal models of BCR/ABL-induced leukemias.

Chronic myelogenous leukemia (CML) serves as a valuable paradigm for understanding the molecular genetic origins of cancer. The cytogenetic standard of diagnosis, the Philadelphia chromosome, has been superseded by a molecular definition for the disease, that of BCR/ABL gene rearrangement. The use of BCR/ABL to recreate CML in mice fulfills Koch's postulates for molecular pathogenesis. The present murine systems facilitate research into the biology of BCR/ABL-induced leukemias, but fall short in their promise to provide models for testing new therapies for CML. A transgenic strain of mice with an inheritable predisposition to CML would be an invaluable tool.